PRESS RELEASE

Temedica wins further renowned industry representatives for expert advisory board

• Temedica announces the expansion of its expert advisory board, which provides strategic support for company growth, access to unique networks and acts as sparring partner
• With Dr. Diane Seimetz, Dr. Stefan Oschmann and Prof. Dr. Dr. Sebastian Schneeweiss, the advisory board is complemented by proven experts from the fields of drug approval, the pharmaceutical industry and real-world evidence

Munich, 26.04.2022 - Temedica GmbH, a leading digital health and health insights company, announced today the expansion of its expert advisory board, with three high-profile members from the fields of drug regulatory affairs, the pharmaceutical industry and real-world evidence. Dr. Diane Seimetz, Dr. Stefan Oschmann and Prof. Dr. Dr. Sebastian Schneeweis will advise Temedica on its strategic development, support the management with their networks, and act as sparring partners. Dr. Rainer Hess, Prof. Dr. Norbert Klusen and Rudi Lamprecht will continue to serve on the expert advisory board (https://temedica.com/en/about-us/#experts).

Gloria Seibert, Founder & Chief Executive Officer at Temedica, said:

"We are proud to win further internationally renowned personalities for our expert advisory board. They share our vision of personalized and data-based patient care and support us with sound expertise and valuable experience. With Dr. Seimetz, Dr. Oschmann, and Prof. Dr. Dr. Schneeweiss, we expand our advisory board with high-caliber and broad expertise. We are very much looking forward to working with our expanded Advisory Board, whose exceptional experience will continue to establish Temedica's position as the leading provider of real-world evidence and patient-generated insights."

With over 20 years of experience, Dr. Diane Seimetz is a leading expert in drug development and regulatory affairs and an experienced entrepreneur and manager in the biopharmaceutical sector. Since 2013, the co-founder and former Managing Director of Biopharma Excellence has been advising clients on clinical development and regulatory approval of novel therapies with the aim of making innovations available to patients early. Previously, Dr. Seimetz held a position as an Executive Vice President at Fresenius Health Care Group, being responsible for the international development of first-in-class biologic drugs. She is a member of several advisory boards and committees, including the Helmholtz Validation Fund and the Dutch Aglaia Oncology Fund. A doctoral pharmacist by trade, Dr. Seimetz is also a board member of Cumulus Oncology.

Dr. Stefan Oschmann is a proven pharma expert and an international top manager with over 30 years of experience. Dr. Oschmann was a member of the Executive Board of Darmstadt-based Merck KGaA for ten years, during five of which he served as Chairman and CEO as well as President of the World Federation of Pharmaceutical Associations IFPMA. He was largely responsible for the transformation of Merck KGaA into a leading international science and technology company and has driven numerous digital innovations and business models. The Doctor of Veterinary Medicine joined Merck KGaA in 2011 from the American pharmaceutical company Merck Sharp & Dohme (MSD). Since 2017, he has been President of the European Federation of Pharmaceutical Industries and Associations (EFPIA), the most prominent European association representing the interests of the pharmaceutical industry.

Dr. Stefan Oschmann said:

"I am impressed by Temedica's development, entrepreneurial drive and vision to support the further development of personalized medicine with new and innovative data and insights. Thanks to digitalization, we have more information available today than ever before, which now needs to be put into the right context to create added value for research and patient care. I am delighted to join Temedica as part of their expert advisory board and to help harness the enormous potential of real-world evidence for the entire industry."

Prof. Dr. Dr. Sebastian Schneeweiss is Professor of Medicine and Epidemiology at Harvard Medical School and Chief of the Division of Pharmacoepidemiology at the Brigham and Women's Hospital in Boston. As a physician and epidemiologist, he is internationally recognized for his work on the analysis of complex digital health data. His research centers on methods that assess the effectiveness of medical products in clinical practice by analyzing healthcare databases in a way that allows causal conclusions. Prof. Schneeweiss' research informs regulatory agencies worldwide and is supported by numerous NIH grants. He is Principal Investigator of the Sentinel Innovation Center of the US Food and Drug Administration (FDA), past president of the International Society for Pharmacoepidemiology and co-founder of Aetion.

The existing advisory board members - Dr. Rainer Hess, an experienced lawyer specializing in medical and health law and former chairman of the Federal Joint Committee (G-BA); Prof. Dr. Norbert Klusen, long-time manager in the health, electronics, and mechanical engineering industries and professor for international health policy and health system comparisons at Leibniz University Hanover; and Rudi Lamprecht, experienced manager from the IT industry at Hewlett Packard and Siemens - will continue their mandates. With the expansion of the expert advisory board, Temedica takes into account its potential further development in the areas of real-world evidence and health insights.

About Temedica GmbH

Temedica is a Munich, Germany-based digital health and health insights company with the mission to bring the patient into the center of healthcare. The company develops state-of-the-art digital patient companions for complex, chronic conditions. These apps support patients with personalized guidance and help them navigate healthcare systems by considering their individual needs. Through direct and long-term interaction with patients, Temedica generates unique and previously unknown real-world evidence about disease progression and the individual effectiveness of therapies. Temedica has expertise in the personalized support of patients as well as in compiling, structuring, and analyzing respective health data. Its data analytics platform Permea is designed to enable unique insights along the entire healthcare value chain and patient journey. Temedica is supported by a consortium of renowned investors with longstanding track-records in the biopharmaceutical industry, including the founding investors of BioNTech. Further information is available at https://temedica.com/en/.

For further information, please contact:

MC Services AG
Dr. Brigitte Keller, Katja Arnold
T +49 89 210228 0
UK: Shaun Brown
T +44 7867 515 918
Email: temedica@mc-services.eu